Medexus Pharmaceuticals Inc.
MEDXF
$2.39
$0.104.15%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.36% | 0.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.36% | 0.51% | |||
| Cost of Revenue | 9.22% | 1.34% | |||
| Gross Profit | -1.30% | 0.07% | |||
| SG&A Expenses | -5.87% | -2.05% | |||
| Depreciation & Amortization | -0.16% | 0.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.43% | -2.85% | |||
| Operating Income | 1.33% | 94.47% | |||
| Income Before Tax | 236.39% | -153.17% | |||
| Income Tax Expenses | 3,150.00% | -112.12% | |||
| Earnings from Continuing Operations | 125.40% | -161.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 125.40% | -161.05% | |||
| EBIT | 1.33% | 94.47% | |||
| EBITDA | 0.44% | 24.57% | |||
| EPS Basic | 125.51% | -161.25% | |||
| Normalized Basic EPS | 960.00% | -300.00% | |||
| EPS Diluted | 125.00% | -162.50% | |||
| Normalized Diluted EPS | 960.00% | -300.00% | |||
| Average Basic Shares Outstanding | 0.44% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.44% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||